Details for Patent: 8,962,630
✉ Email this page to a colleague
Which drugs does patent 8,962,630 protect, and when does it expire?
Patent 8,962,630 protects KISQALI and KISQALI FEMARA CO-PACK (COPACKAGED) and is included in two NDAs.
Protection for KISQALI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty-two patent family members in forty-eight countries.
Summary for Patent: 8,962,630
| Title: | Pyrrolopyrimidine compounds and their uses |
| Abstract: | The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein. |
| Inventor(s): | Christopher Thomas Brain, Moo Je Sung, Bharat Lagu |
| Assignee: | Astex Therapeutics Ltd , Novartis Pharmaceuticals Corp |
| Application Number: | US13/786,955 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,962,630 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,962,630
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | KISQALI | ribociclib succinate | TABLET;ORAL | 209092-001 | Mar 13, 2017 | RX | Yes | Yes | 8,962,630*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Novartis | KISQALI FEMARA CO-PACK (COPACKAGED) | letrozole; ribociclib succinate | TABLET;ORAL | 209935-001 | May 4, 2017 | RX | Yes | Yes | 8,962,630*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,962,630
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2331547 | ⤷ Start Trial | 300909 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2331547 | ⤷ Start Trial | PA2017039 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2331547 | ⤷ Start Trial | CR 2017 00060 | Denmark | ⤷ Start Trial |
| European Patent Office | 2331547 | ⤷ Start Trial | 122017000102 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
